36,252 Novo Nordisk A/S $NVO Shares Bought by Kestra Advisory Services LLC

Kestra Advisory Services LLC raised its holdings in Novo Nordisk A/S (NYSE:NVO) by 24.9% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 182,097 shares of the company’s stock after purchasing an additional 36,252 shares during the quarter. Kestra Advisory Services LLC’s holdings in Novo Nordisk A/S were worth $6,903,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. CoreCap Advisors LLC grew its holdings in shares of Novo Nordisk A/S by 4.7% during the second quarter. CoreCap Advisors LLC now owns 5,341 shares of the company’s stock worth $256,000 after buying an additional 242 shares during the last quarter. Claro Advisors Inc. increased its position in Novo Nordisk A/S by 1.2% in the 3rd quarter. Claro Advisors Inc. now owns 21,868 shares of the company’s stock valued at $829,000 after acquiring an additional 256 shares during the period. Carson Advisory Inc. raised its stake in Novo Nordisk A/S by 2.2% during the 1st quarter. Carson Advisory Inc. now owns 12,316 shares of the company’s stock valued at $453,000 after acquiring an additional 268 shares during the last quarter. Byrne Asset Management LLC raised its stake in Novo Nordisk A/S by 9.7% during the 3rd quarter. Byrne Asset Management LLC now owns 3,055 shares of the company’s stock valued at $114,000 after acquiring an additional 270 shares during the last quarter. Finally, Bradley Foster & Sargent Inc. CT raised its stake in Novo Nordisk A/S by 0.6% during the 1st quarter. Bradley Foster & Sargent Inc. CT now owns 46,960 shares of the company’s stock valued at $1,726,000 after acquiring an additional 272 shares during the last quarter. 11.54% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on NVO shares. Jefferies Financial Group reaffirmed a “neutral” rating on shares of Novo Nordisk A/S in a research report on Monday, September 21st. DZ Bank reissued a “neutral” rating on shares of Novo Nordisk A/S in a report on Thursday, August 6th. BMO Capital Markets set a $40.00 price target on Novo Nordisk A/S and gave the stock a “market perform” rating in a research note on Monday, October 12th. Citigroup restated a “neutral” rating on shares of Novo Nordisk A/S in a research note on Friday, October 9th. Finally, Cfra downgraded Novo Nordisk A/S from a “hold” rating to a “sell” rating and set a $38.00 price target for the company. in a report on Tuesday, September 22nd. Five research analysts have rated the stock with a Buy rating, sixteen have given a Hold rating and five have assigned a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $59.44.

Recent Novo Nordisk A/S Headlines

These are some of the NVO headlines that stood out recently:

• Positive Sentiment: Novo’s Wegovy pill recorded DKK 5.4 billion in third-quarter sales, a potential growth driver as access expands. However, competition in the GLP-1 market remains intense, and a higher-dose Wegovy version may be important to reviving momentum. Article: Will Wegovy Pill Drive Renewed GLP-1 Growth Momentum for Novo Stock?
• Negative Sentiment: The FDA is requiring GLP-1 makers to add warnings about rare NAION-related vision loss to labels for drugs including Wegovy. Although the risk is rare and the warning covers competitors’ medicines too, it could raise safety concerns among patients and investors. Article: FDA warns of vision loss risk linked to popular GLP-1 drugs
• Negative Sentiment: Novo was among European ADRs hit in a broad market selloff, an external source of pressure rather than company-specific news. Separately, a report said its buyback was nearing its ceiling, potentially limiting further support from repurchases. Article: European ADR Selloff Hits a Broad Range of Stocks

Novo Nordisk A/S Trading Up 1.1%

NYSE NVO opened at $41.13 on Thursday. The company has a quick ratio of 0.64, a current ratio of 0.84 and a debt-to-equity ratio of 0.54. The stock has a market capitalization of $183.65 billion, a P/E ratio of 10.36, a P/E/G ratio of 1.40 and a beta of 0.70. Novo Nordisk A/S has a 52-week low of $35.12 and a 52-week high of $64.16. The firm has a 50-day moving average price of $40.32 and a 200 day moving average price of $43.56.

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish pharmaceutical company focused on treatments for diabetes, obesity and other serious chronic diseases. Its portfolio includes insulin and other diabetes medicines, as well as obesity treatments such as Wegovy and diabetes treatments such as Ozempic and Rybelsus. The company also develops medicines for rare blood and endocrine disorders, including hemophilia and growth disorders. Its products are sold in markets around the world. Novo Nordisk traces its roots to Danish insulin companies founded in the 1920s; the two organizations that became Novo Nordisk merged in 1989.